




CME FOUNDATION OF INDIA



**NOVEL THERAPY TO
TREAT CKD ANEMIA IN INDIA**

EVENT REPORT

About Workshop

The **CME Foundation of India**, organized an academic workshop on **Novel Therapy to Treat CKD Anemia in India** on 28th January 2026 at ESIC Medical College & Hospital, Bharat Nagar, Ludhiana. The session aimed to address the unmet clinical needs in the management of anemia associated with chronic kidney disease (CKD) and to explore emerging therapeutic approaches in this domain.

The workshop was attended by physicians and nephrologists from ESIC Hospital and surrounding centers. The session by **Dr. Rajan Isaacs**, covered multiple aspects of CKD anemia management such as understanding the growing challenge in CKD anemia, limitations of current therapies, desidustat as a novel therapy in CKD management, its mechanism, and practical integration in clinical practice.

Date: 28th January 2026

Venue: ESIC Medical College & Hospital, Bharat Nagar, Ludhiana

No. of participants: 45

Agenda

Date: 28th January 2026

Time: 1:00 p.m. to 2:00 p.m.

Topics	Speaker	Timings
Registration		1:00 p.m. to 1:10 p.m.
Welcome Note		1:10 p.m. to 1:15 p.m.
Novel Therapy to Treat CKD Anemia in India	Dr. Rajan Isaacs M.B.B.S., M.D. (Medicine), D.N.B. (Nephrology), AIIMS	1:15 p.m. to 1:55 p.m.
Vote of Thanks		1:55 p.m. to 2:00 p.m.

Summary of the Novel Therapy to Treat CKD Anemia in India

The scientific session commenced with an in-depth discussion on the evolving landscape of anemia associated with chronic kidney disease (CKD) in India. Dr. Rajan Isaacs set the context by underscoring the growing clinical and economic burden of CKD-related anemia and its far-reaching impact on patient outcomes, quality of life, and healthcare systems.

Understanding the Complexity and Growing Burden of CKD-Related Anemia

During the opening address, Dr. Rajan Isaacs highlighted the multifactorial nature of anemia in CKD. He highlighted the growing burden of anemia and its significance in CKD population. He explained that factors such as iron deficiency, chronic inflammation, and impaired endogenous erythropoietin production interact in complex ways, making anemia management particularly challenging. This complexity, he noted, necessitates therapeutic approaches that address multiple underlying pathways rather than relying solely on conventional strategies.

Limitations of Existing Treatment Paradigms

The discussion then transitioned to current standards of care, including erythropoiesis-stimulating agents (ESAs) and iron supplementation. Dr. Rajan Isaacs outlined key challenges associated with these therapies, such as variable treatment response, safety considerations, and limited accessibility in the Indian healthcare setting. He emphasized that these limitations often lead to inadequate hemoglobin control, frequent dose modifications, and reduced patient adherence, thereby leaving important unmet needs in CKD anemia management.

Spotlight on Desidustat: Advancing Anemia Care

A key highlight of the session was the introduction of Desidustat, a novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Dr. Rajan Isaacs described its unique mechanism of action, which involves stimulating endogenous erythropoietin production, improving iron metabolism, and reducing hepcidin levels. By targeting multiple contributors to anemia, Desidustat was presented as a promising oral alternative to injectable ESAs, with the potential to enhance convenience and treatment adherence.

Clinical Evidence and Real-World Experience

Dr. Rajan Isaacs reviewed evidence from pivotal clinical trials demonstrating Desidustat's ability to effectively increase and sustain hemoglobin levels across a broad spectrum of CKD patients. He also highlighted its favorable safety and tolerability profile. Complementing the trial data, real-world

clinical experience was shared, reinforcing Desidustat's utility in both dialysis-dependent and non-dialysis-dependent CKD populations.

Translating Evidence into Practice

The session concluded with practical insights into the integration of Desidustat into routine clinical practice. Key considerations discussed included appropriate patient selection, dosing and titration strategies, monitoring requirements, and long-term management goals. Participants gained actionable guidance aimed at optimizing anemia control, improving adherence, and ultimately enhancing patient-centered outcomes in CKD care.

At the end of the Conclave, the CME Foundation of India extended its sincere gratitude to the speaker and delegates for attending the conclave and acknowledged Zydus Lifesciences Ltd., the industry partner, for their valuable support and contribution to the success of the Conclave.

Snapshots of Success

Lecture on Novel Therapy to Treat CKD Anemia in India



Lecture on Novel Therapy to Treat CKD Anemia in India





Developed by:

CME FOUNDATION OF INDIA

Building "A" Sahney Business Centre, 27 Kirol Road, Vidyavihar (W), Mumbai - 400086
Tel: +91 22 61798600 | Website: www.cmefi.co.in